STADA sells Irish production facility and thus continues to be in line with planning for the implementation of 'STADA - build the future'

STADA Arzneimittel AG  / Key word(s): Disposal

06.02.2012 16:21

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, February 6, 2012 - STADA Arzneimittel AG (hereinafter 'STADA'),
Bad Vilbel, has signed and completed contracts today, on February 6, 2012,
with the mutares Group, Munich, for the sale of the Irish production
facility STADA Production Ireland Ltd. (hereinafter 'SPI'), Clonmel, which
has to date been a part of the STADA Group through the STADA subsidiary
Clonmel Healthcare Ltd. (hereinafter 'Clonmel'). The contracts were
concluded retroactively to January 1, 2012.

The sale, which represents an important step in the Group-wide cost
efficiency program 'STADA - build the future' which was introduced in 2010
(see the Company's ad hoc release from June 7, 2010 as well as STADA's
Interim Report on the first nine months of 2011), results in a one-time
earnings burden in the amount of approx. EUR 16.6 million before or approx.
EUR 16.5 million after taxes, which will be reported by STADA in the first
quarter of 2012 as a one-time special effect.

The transaction will be carried out in the form of a so-called 'share deal'
with which all shares in SPI and thus also conditions of employment for all
of the approx. 180 employees at the facility as well as the other
contractual relationships are immediately transferred to the mutares Group.
In addition, as part of this transaction, the production facilities,
corresponding assets as well as the property will be transferred to the
buyer within the scope of a lease option model over a period of four years.

The products that are currently being produced in the Irish production
facilities for the STADA Group, will continue to be produced by SPI for
STADA during a transitional period.
 
With the sale of the Irish production facility, STADA continues to be in
line with the ongoing implementation of the Group-wide cost efficiency
program 'STADA - build the future' (see the Company's ad hoc release of
June 7, 2010); the one-time burden that has now been incurred is below the
expense originally calculated within the scope of the program. In addition,
the already initiated successive transfer of the production volumes from
the Irish production facilities to other STADA production facilities will
improve capacities there and thus reduce unit prices of the relevant
products over the medium term.


About the mutares Group:
mutares AG, Munich (www.mutares.de), acquires midsized companies in whole
and in part, which are sold as a result of a repositioning process at their
owners and which exhibit a clear operational improvement potential. Getting
engaged with its own teams, mutares actively supports its portfolio
companies to generate significant value increase. The focus of the
operational work is to ensure sustainable, long-term growth. The shares of
mutares AG are listed at the Open Market segment of the Berlin stock
exchange (symbol: MUX, ISIN: DE000A0SMSH2).


Additional information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Tel.: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-Mail:
communications@stada.de /
Or visit us in the Internet at www.stada.com.


06.02.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
              Germany
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
              Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------